Rivus therapeutics
WebMar 29, 2024 · BRIEF—Rivus Pharma presents results from a Phase IIa trial of HU6 07-11-2024 US clinical-stage biopharma firm Rivus Pharmaceuticals has presented positive top-line results from a Phase IIa trial evaluating the safety and efficacy of HU6, a first-in-class controlled metabolic accelerator (CMA), to address liver fat and total body fat in patients … WebJul 20, 2024 · Rivus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to improving cardio-metabolic health, today announced the completion of a $35 million Series A financing.Rivus is advancing a new class of oral, once daily, small molecule therapeutics called Controlled Metabolic Accelerators (CMAs), designed to improve cellular …
Rivus therapeutics
Did you know?
WebJul 22, 2024 · Rivus Pharmaceuticals, Inc., a Charlottesville, Va.-based biopharmaceutical company dedicated to improving cardio-metabolic health, closed a $35m Series A … WebUnder his leadership, the asset-centric approach to life sciences investing was conceived and adopted. Francesco currently serves on the boards of a number of portfolio companies, including Centessa Pharmaceuticals, Rivus Pharmaceuticals, Levicept, Granular Therapeutics and Kaerus.
WebSep 22, 2024 · Rivus Pharmaceuticals Inc. has completed a $132 million series B financing round. It was led by RA Capital Management with participation from Bain Capital Life Sciences, BB Biotech AG and existing investors Longitude Capital, Medicxi and RxCapital.. The financing will further support clinical advancement of lead candidate HU6, a first-in … WebApr 12, 2024 · Nonalcoholic fatty liver disease (NAFLD) consists of a spectrum starting from NAFLD that may progress to, nonalcoholic steatohepatitis (NASH) which can lead to fibrosis, cirrhosis, hypercellular carcinoma, or even liver failure. The prevalence of NASH has increased in parallel with the rising rate of obesity and type 2 diabetes. Given the high …
WebSep 22, 2024 · Rivus Pharmaceuticals, Inc., a leader in mitochondrial biology, is dedicated to improving cardio-metabolic health by advancing a new class of medicines, Controlled …
WebScilex Holding Company, a Sorrento Company, enters into an agreement for an exclusive license with ROMEG Therapeutics, LLC, for the right to commercialize Gloperba®, an FDA-approved prophylactic treatment for painful gout flares in adults, in the US. January 31, 2024. Visit our LinkedIn Page .
WebJul 9, 2024 · Drug: HU6. Phase 1. Detailed Description: This is a single ascending dose trial in healthy volunteers. The study will be conducted in up to 7 cohorts. Upon review of the safety and PK data, it may be decided to expand the current cohort versus dose escalate to the next cohort. In addition, the sponsor may elect not to enroll all 7 cohorts based ... diana kazakovaWebJan 6, 2024 · Mr. Enright currently serves on the boards of Aptinyx (APTX), CuraSen Therapeutics, Dascena, Epirium Bio (formerly Cardero Therapeutics), Jazz … bear paradox bow manualWebPharmaceutical Research and Manufacturers of America diana kim england jewelryWebOverview. Third Harmonic Bio is a clinical-stage biopharmaceutical company that is advancing the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory and gastrointestinal diseases. We are developing a novel highly selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as ... diana kids programWebRivus Pharmaceuticals Overview. Founded Year 2024. Location Charlottesville, United States. Company Stage Series A. Total Funding $35M. Last Funding Round $35M, Series A, Jun 20, 2024. Similar Cos. Sarepta, Tenaya Therapeutics, Esperion Therapeutics, Portola Pharma, Aegerion & 298 others Disclaimer: Total Funding = Total Disclosed Equity … bear paradox kaufenWebJul 20, 2024 · Rivus Pharmaceuticals General Information. Description. Developer of controlled metabolic accelerators created to improve cardio-metabolic health. The company's accelerators are designed to improve cellular metabolism and treat the underlying cause of highly prevalent metabolic and cardiovascular diseases, providing … bear paradox manualWebBrian Liu, MD, is a Principal at Longitude Capital. Dr. Liu is a board observer at Quanta Therapeutics and Rivus Pharmaceuticals. He previously served as a board observer at Endeavor Biomedicines, Inflazome (acquired by Roche), Talaris Therapeutics (TALS), and Vera Therapeutics (VERA). diana knezevici